Turner Syndrome Clinical Trial
Official title:
The Use of Norditropin® in Turner's Syndrome
Verified date | February 2017 |
Source | Novo Nordisk A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial is conducted in Europe. The aim of this trial is to study the dose-response relationship and effect of somatropin (Norditropin®) on final height in girls with Turner Syndrome.
Status | Completed |
Enrollment | 57 |
Est. completion date | April 11, 2004 |
Est. primary completion date | April 11, 2004 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 2 Years to 11 Years |
Eligibility |
Inclusion Criteria: - Turner Syndrome - Not previously treated with growth hormone or androgen - Well-documented height over the previous 12 months - Informed consent of parents (and child if appropriate) Exclusion Criteria: - Growth hormone (GH) deficiency based on a GH stimulation test |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Novo Nordisk Investigational Site | Crawley |
Lead Sponsor | Collaborator |
---|---|
Novo Nordisk A/S |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Final height in cm | |||
Secondary | Ratio between change in bone age and change in chronological age | |||
Secondary | Age at onset of puberty | |||
Secondary | Adverse events |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01734486 -
Growth Response in Girls With Turner Syndrome
|
Phase 4 | |
Completed |
NCT01678261 -
X-chromosome Inactivation, Epigenetics and the Transcriptome
|
N/A | |
Completed |
NCT01419249 -
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study
|
Phase 4 | |
Recruiting |
NCT04948658 -
Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
|
||
Completed |
NCT01563926 -
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
|
Phase 3 | |
Completed |
NCT02787486 -
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
|
||
Completed |
NCT00877942 -
Sex Differences in Early Brain Development; Brain Development in Turner Syndrome
|
N/A | |
Completed |
NCT00825617 -
Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy
|
N/A | |
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT01245374 -
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
|
Phase 4 | |
Completed |
NCT01322165 -
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
|
N/A | |
Terminated |
NCT00419107 -
Beta Cell Function in Women With Turner Syndrome
|
N/A | |
Active, not recruiting |
NCT00625001 -
Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome
|
N/A | |
Completed |
NCT00029159 -
The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome
|
Phase 3 | |
Completed |
NCT01518062 -
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
|
Phase 4 | |
Completed |
NCT00471731 -
Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure
|
N/A | |
Completed |
NCT00256126 -
Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®
|
Phase 4 | |
Completed |
NCT03181230 -
Health, Fitness, and Quality of Life in Adolescent Girls With Turner Syndrome
|
||
Completed |
NCT02160717 -
Risk of Diabetes in Young Turner Syndrome Patients
|
N/A |